Langley RG, et al. - Researchers assessed integrated safety data from 12-week induction period, a 12–60-week maintenance period, and from all ixekizumab-treated patients from 11 clinical studies in order to investigate the long-term safety of ixekizumab in psoriasis treatment. They identified a total of 5,689 patients who accounted for 12,061.5 patient-years of ixekizumab exposure from 11 studies. Outcomes indicated no new safety signals in relation to ixekizumab long-term maintenance treatment for 3-year in patients with moderate-to-severe plaque psoriasis. Over 156 weeks, 83.9% of patients reported treatment-emergent adverse events (AEs), with 11.8% of patients reporting serious AEs. Mucocutaneous candidiasis was the most reported opportunistic infections.